At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAMS NEWAMSTERDAM PHARMA CO NV
Closed 07-10 16:00:00 EDT
35.26
-0.66
-1.84%
盘后35.26
+0.000.00%
17:22 EDT
High36.17Low34.15Vol564.26K
Open36.01D1 Closing35.92Amplitude5.62%
Mkt Cap4.12BTradable Cap3.18BTotal Shares116.90M
T/O19.78MT/O Rate0.63%Tradable Shares90.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Did NewAmsterdam’s (NAMS) Alzheimer’s Biomarker Signal Just Recast Obicetrapib’s Dual-Disease Investment Narrative?
Simply Wall St.  ·  07-09 20:28
Did NewAmsterdam’s (NAMS) Alzheimer’s Biomarker Signal Just Recast Obicetrapib’s Dual-Disease Investment Narrative?
Newamsterdam Pharma Grants 28,700 Inducement Share Options Priced at $35.17
Reuters  ·  07-03
Newamsterdam Pharma Grants 28,700 Inducement Share Options Priced at $35.17
Newamsterdam Pharma to Present Obicetrapib Data for Early Alzheimer’s Prevention at AAIC 2026
Reuters  ·  07-01
Newamsterdam Pharma to Present Obicetrapib Data for Early Alzheimer’s Prevention at AAIC 2026
NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says
MT Newswires Live  ·  06-30
NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says
RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  06-30
RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk
Newamsterdam Pharma Chief Accounting Officer Louise Kooij Sells USD 1.21 Million in Shares
Reuters  ·  06-25
Newamsterdam Pharma Chief Accounting Officer Louise Kooij Sells USD 1.21 Million in Shares
NewAmsterdam Pharma posts real-world study presentation on high-intensity statin intolerance, adverse events
Reuters  ·  06-17
NewAmsterdam Pharma posts real-world study presentation on high-intensity statin intolerance, adverse events
Did Druckenmiller’s Spotlight and ESOP Shelf Just Reframe NewAmsterdam Pharma’s (NAMS) Obicetrapib Story?
Simply Wall St.  ·  06-09
Did Druckenmiller’s Spotlight and ESOP Shelf Just Reframe NewAmsterdam Pharma’s (NAMS) Obicetrapib Story?
NewAmsterdam Pharma to present obicetrapib data at National Lipid Association Scientific Sessions
Reuters  ·  06-03
NewAmsterdam Pharma to present obicetrapib data at National Lipid Association Scientific Sessions
NewAmsterdam Pharma shareholders approve 2026 employee stock purchase plan at annual meeting
Reuters  ·  06-03
NewAmsterdam Pharma shareholders approve 2026 employee stock purchase plan at annual meeting
NewAmsterdam Pharma joins Jefferies Global Healthcare Conference fireside chat
Reuters  ·  05-28
NewAmsterdam Pharma joins Jefferies Global Healthcare Conference fireside chat
NewAmsterdam Pharma Chief Accounting Officer Louise Kooij reports $ 2.32 million share sale
Reuters  ·  05-28
NewAmsterdam Pharma Chief Accounting Officer Louise Kooij reports $ 2.32 million share sale
Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones
Simply Wall St.  ·  05-11
Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones
Stock Track | NewAmsterdam Pharma Soars 5.19% Intraday on Anticipation of Upcoming Conference Presentations
Stock Track  ·  05-11
Stock Track | NewAmsterdam Pharma Soars 5.19% Intraday on Anticipation of Upcoming Conference Presentations
Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (TMCI), NewAmsterdam Pharma Company (NAMS) and LENSAR (LNSR)
TIPRANKS  ·  05-11
Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (TMCI), NewAmsterdam Pharma Company (NAMS) and LENSAR (LNSR)
NewAmsterdam Pharma to present at BofA Securities Health Care Conference
Reuters  ·  05-11
NewAmsterdam Pharma to present at BofA Securities Health Care Conference
Stock Track | NewAmsterdam Pharma Soars 5.31% Intraday on Guggenheim's Buy Rating
Stock Track  ·  05-08
Stock Track | NewAmsterdam Pharma Soars 5.31% Intraday on Guggenheim's Buy Rating
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  05-08
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  05-08
Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31 - Earnings Summary

Introduction

Company Name.
NEWAMSTERDAM PHARMA CO NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Issue price:
--